Caplight Directory>Companies>Re-Vana Therapeutics-preview>Revanatx


Re-Vana Therapeutics

Re-Vana Therapeutics

Private
BelfastN/Ahttps://www.revanatx.com/

Last Round

Series A

Nov 30, 2022

Total Funding Raised

$17.46M

Company Overview

Re-Vana Therapeutics is a biotechnology company developing a sustained-release drug delivery platform for ophthalmic diseases.

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Re-Vana Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Re-Vana Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series ANov 30, 2022
GrantMay 1, 2022
Pre SeedJun 2, 2020
GrantAug 5, 2019
SeedNov 27, 2017
View all Funding Rounds

Key People

Founding team and executive leadership

Michael J. O'Rourke

CEO

Executive Team

Re-Vana Therapeutics Investors

Notable investors and investment history

InvestorRounds
QUBISSeed, Pre Seed, Series A
Invest Northern IrelandSeed
Co-Fund NISeries A
Innovate UKGrant
Clarendon Fund ManagersSeed, Pre Seed
Techstart VenturesSeed, Pre Seed, Series A
Visionary VenturesPre Seed, Series A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 8, 2025

    Monthly visitors increased by 87% MoM.

  • Jul 10, 2025

    Monthly visitors grew 414% MoM, from 130 to 668.

View all signals

Re-Vana Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Re-Vana Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Re-Vana Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBelfast
Employee Range23
Year Founded2015
Last FundingNov 30, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.